Metropolis Healthcare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+23.6%+10.2%+5.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+32.3%+7.2%−2.0%
+37.5%+3.3%−5.5%
+31.4%+13.3%−10.4%
−67.5%+13.4%−10.6%
+14.5%+20.1%+3.6%
+14.2%+21.4%+11.0%
+33.5%−0.5%+6.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

METROPOLIS₹553.85

Metropolis Healthcare Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABVIJAYATHYROCAREMARKSANSPARKHOSPSJLHLRUBICONHCGMcap ₹11,483 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+5.2+10.2+23.6—
EBITDA Growth—-2.0+7.2+32.3—
EBIT Growth—-5.5+3.3+37.5—
Net Income Growth—-10.4+13.3+31.4—
EPS Growth—-10.6+13.4-67.5—
Total Assets Growth—+3.6+20.1+14.5—
Total Equity Growth—+11.0+21.4+14.2—
Cash from Operations Growth—+6.9-0.5+33.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.